While there are approved drugs for chronic liver diseases, they have limited success treating fibrosis, their underlying cause. This deficiency suggests that current liver fibrosis models are inadequate and require improvement for more accurate disease recapitulation and predictive drug testing.
To address this gap in liver disease treatment and beyond, scientists are developing better in vitro disease models with decellularized extracellular matrix (dECM) coatings and hydrogels derived from primary tissues. These dECMs provide cells with tissue-specific biochemical and mechanical signals that are missing in other in vitro systems, recreating a native cellular environment for both 2D and 3D cultures.
In this webinar, brought to you by Xylyx, research scientist Andrew Schmidt will discuss his research using liver models made with physiologically relevant dECM that can deliver more predictive results compared to conventional cell culture.
Topics to be covered in this webinar
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
Please enter the e-mail address you would like to be contacted at.